Supportive Care and Management of Treatment-Emergent Adverse Events With Targeted Therapy in Non–Small Cell Lung Cancer
Clell Hasenbank, PharmD
Providence St. Mary Regional Cancer Center, Walla Walla, Washington
Author’s disclosures of potential conflicts of interest are found at the end of this article.
Clell Hasenbank, PharmD, 401 West Poplar Street, Walla Walla, WA 99362. E-mail: email@example.com
J Adv Pract Oncol 2017;8:43–50 |
© 2017 Harborside Press®
This article provides a summary of current approaches to the management of adverse effects from targeted therapies for non–small cell lung cancer (NSCLC). Agents included in this section are categorized as epidermal growth factor receptor (EGFR) inhibitors or anaplastic lymphoma kinase (ALK) inhibitors. Although targeted therapies are generally considered to be better tolerated compared to traditional cytotoxic chemotherapy, adverse events still occur in the majority of patients. Advanced practitioners play prominent roles in side-effect management and are often involved with counseling and education. Providing an overview of treatment guidelines will help advanced practitioners be better prepared to intervene and treat adverse events that, if poorly managed, have the potential to lead to discontinuation of therapy.
For access to the full length article, please sign in